Abstract

[...]the available literature on pediatric treatment strategies for SARS-CoV-2 infection in children was reviewed up to 10 March 2021 on PubMed, the website of national and international scientific societies and of clinical trials. In particular, for the age group 12–17 years, the risk factors are the following: body mass index > 95 percentile for age, sickle cell anemia, congenital or acquired cardiac disease, neurodevelopment disease, device carriers (tracheostomy, gastrostomy, etc.), asthma or other respiratory disorders requiring daily treatment [17, 18]. [...]the best treatment for pediatric COVID-19 is currently not well defined, because randomized trials in children are lacking.

Details

Title
Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper
Author
Venturini, Elisabetta; Montagnani, Carlotta; Garazzino, Silvia; Donà, Daniele; Pierantoni, Luca; Andrea Lo Vecchio; Krzysztofiak, Andrzej; Nicolini, Giangiacomo; Bianchini, Sonia; Galli, Luisa; Villani, Alberto; Guido Castelli Gattinara  VIAFID ORCID Logo  ; the Italian SITIP-SIP SARS-Cov-2 pediatric infection study group
Pages
1-4
Section
Letter to the Editor
Publication year
2021
Publication date
2021
Publisher
BioMed Central
ISSN
17208424
e-ISSN
18247288
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2582920663
Copyright
© 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.